

Quantity Limit

Dihydroergotamine Injectable, Nasal

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
Atzumi	dihydroergotamine mesylate	nasal powder
Brekiya	dihydroergotamine mesylate	injection
Migranal	dihydroergotamine mesylate	nasal spray
Trudhesa	dihydroergotamine mesylate	nasal spray

Indications

FDA-approved Indications

Atzumi

Atzumi is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

Atzumi is not indicated for the preventive treatment of migraine.

Atzumi is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.

Brekiya

Brekiya is indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Limitations of Use

Brekiya is not indicated for the preventive treatment of migraine.

Brekiya is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.

Migranal

Migranal (dihydroergotamine mesylate) Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura.

Migranal (dihydroergotamine mesylate) Nasal Spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine.

Trudhesa

Trudhesa is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

Trudhesa is not indicated for the preventive treatment of migraine.

Trudhesa is not indicated for the management of hemiplegic or basilar migraine.

Initial Limit Quantity

Please Note: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

Limits should accumulate across all drugs and strengths up to highest quantity listed depending on the order the claims are processed.

The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

Drug	1 Month Limit	3 Month Limit
Atzumi (dihydroergotamine mesylate)	12 nasal devices / 25 days	40 nasal devices / 75 days
Brekiya (dihydroergotamine mesylate)	24 autoinjectors (6 cartons) / 25 days	72 autoinjectors (18 cartons) / 75 days
Migranal (dihydroergotamine mesylate)	8 nasal units / 25 days	24 nasal units / 75 days
Trudhesa (dihydroergotamine mesylate)	12 units (3 packages) / 25 days	36 units (9 packages) / 75 days

Reference number(s)
145-H

References

1. Atzumi [package insert]. Durham, NC: Satsuma Pharmaceuticals, Inc.; April 2025.
2. Brekiya [package insert]. Bridgewater, NJ. Amneal Specialty; May 2025.
3. Migranal Nasal Spray [package insert]. Bridgewater, NJ: Bausch Health US, LLC; September 2022.
4. Trudhesa [package insert]. Seattle, WA: Impel NeuroPharma Inc; August 2023.
5. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024.
<https://online.lexi.com>. Accessed April 1, 2024.
6. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at:
<https://www.micromedexsolutions.com/> (cited: 04/1/2024).